Top Companies and Market Competition in the Iron Chelation Therapy Sector

The iron chelation therapy market is positioned for substantial growth in the coming years, driven by advances in treatment approaches and an increased focus on patient-centered care. As demand rises for safer and more effective therapies to manage iron overload, this market is expected to evolve with innovative solutions and expanding therapeutic options.

Projected Market Growth in Iron Chelation Therapy by 2030
The iron chelation therapy market is forecasted to reach a value of $3.68 billion by the year 2030, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This positive trajectory is largely fueled by the growing adoption of individualized treatment plans designed around patient needs, the ongoing development of next-generation chelation agents, and the expansion of home-based iron management programs. Additionally, there is increasing attention to reducing side effects associated with iron chelation treatments and a rising investment in therapies targeting rare diseases. Key trends shaping the market include a growing preference for oral iron chelation medications, enhanced efforts to improve patient compliance and adherence, more widespread use of personalized iron management strategies, greater emphasis on long-term monitoring of iron overload, and the advancement of modified-release drug formulations.

Download a free report of the iron chelation therapy market report:
https://www.thebusinessresearchcompany.com/report/iron-chelation-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Players Influencing the Iron Chelation Therapy Market
Several prominent pharmaceutical companies hold significant positions in the iron chelation therapy landscape. These include Novartis AG, Bayer AG, Vifor Pharma Group, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Cipla Ltd., Zydus Cadila, Natco Pharma Ltd., Apotex Inc., Mylan NV (Viatris Inc.), Chiesi Farmaceutici S.pA., Lupin Limited, Taro Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., Accord Healare, Sandoz International GmbH, Recordati S.p.A., Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., and Keryx Biopharmaceuticals Inc.

Significant Acquisition Expanding Market Presence
In September 2024, France-based Mitem Pharma acquired worldwide rights to DESFERAL (deferoxamine mesylate) from Novartis AG, though the financial terms were not disclosed. This strategic acquisition enables Mitem Pharma to strengthen its foothold in the iron chelation therapy sector by adding a well-established treatment option for iron overload disorders to its portfolio. Novartis AG, headquartered in Switzerland, remains a key player in providing iron chelation therapies globally.

View the full iron chelation therapy market report:
https://www.thebusinessresearchcompany.com/report/iron-chelation-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Shaping the Future of Iron Chelation Therapy
Industry leaders are increasingly concentrating on innovative product development to improve patient outcomes and minimize complications. One notable area of focus is the creation of composite meshes-surgical implants combining both absorbable and non-absorbable materials-aimed at offering durable support alongside enhanced biocompatibility. Such innovations are particularly relevant for procedures like hernia repair, where improved healing and reduced post-surgical issues are critical.

For example, in April 2025, US-based company W. L. Gore & Associates introduced the GORE SYNECOR Preperitoneal Biomaterial across Europe, the Middle East, and South Africa. This next-generation composite surgical mesh is designed to support tension-free, minimally invasive hernia repairs by combining a permanent polytetrafluoroethylene (PTFE) layer with a bioabsorbable scaffold made from polyglycolide-co-trimethylene carbonate (PGA:TMC). This combination enhances tissue integration, promotes vascularization, and supports better postoperative recovery.

Comprehensive Segmentation of the Iron Chelation Therapy Market
The iron chelation therapy market can be segmented into several categories to aid detailed analysis:

1) Drug Type:
- Deferasirox
- Deferoxamine
- Deferiprone

2) Route of Administration:
- Intravenous Administration
- Subcutaneous Delivery

3) Indication:
- Thalassemia
- Sickle Cell Disease
- Myelodysplastic Syndromes (MDS)
- Non-Transfusion-Dependent Thalassemia (NTDT)

4) Patient Demographics:
- Pediatric Patients
- Adult Patients
- Elderly Patients

5) End-User:
- Hospitals
- Specialty Clinics
- Homecare Settings
- Other End-Users

Further subcategories include:
- Deferasirox forms such as Dispersible Tablets (DT), Film-Coated Tablets (FCT), and Oral Suspension
- Deferoxamine formulations including Injectable Solution, Subcutaneous Infusion, Intramuscular Injection, and Intravenous Infusion
- Deferiprone dosage forms like Oral Solution, Oral Tablets, and Modified-Release Tablets

This detailed segmentation supports a thorough understanding of market dynamics across different drug types, patient groups, administration routes, and care settings.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.